In:
Thoracic Cancer, Wiley, Vol. 7, No. 5 ( 2016-09), p. 564-569
Abstract:
A prospective study was performed on the use of chemoradiotherapy ( CRT ) for esophageal cancer (EC) with involved‐field radiation therapy ( IFRT ), based on 18‐fluorodeoxyglucose positron‐emission tomography. Prognostic factors for overall survival ( OS ) were analyzed. Methods Eligible patients included 63 adults with newly diagnosed, untreated, inoperable stage I–IV EC with lymph node metastases. Patients received 80 mg/m 2 nedaplatin per day on day 1, 800 mg/m 2 5‐fluorouracil on days 1–4 intravenously repeated every 28 days for two to four cycles, and combined IFRT . Irradiation was applied only to the primary tumor and positive lymph nodes. Results Three‐year progression‐free survival and OS rates were 44.9% and 47.5%, respectively. The median survival time was 31.5 months. In univariate analyses for OS , Karnofsy Performance Scale 〈 90% ( P = 0.027), initial stage ( P = 0.0087), T stage ( P = 0.066), N stage ( P = 0.000086), M stage of M1 ( P = 0.0042), dysphagia score ( P = 0.00017), tumor marker squamous cell carcinoma antigen 〉 1.5 ng/mL ( P = 0.0054), gross tumor volume ( GTV ) 〉 60 cc ( P = 0.00011), and relative dose intensity ( RDI ) of chemotherapy ≤50% ( P = 0.063) were found to be associated with significantly or marginally worse OS. In multivariate analyses for OS , GTV ≥ 60 cc ( P = 0.00040), RDI 〈 50% ( P = 0.00034), and cN2‐3 ( P = 0.0020) were associated with significantly worse OS . Conclusion GTV, RDI and N grading, were associated with OS after definitive CRT using IFRT for EC.
Type of Medium:
Online Resource
ISSN:
1759-7706
,
1759-7714
DOI:
10.1111/tca.2016.7.issue-5
DOI:
10.1111/1759-7714.12369
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2559245-2
